CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
Xinyuan Liu, Juan-juan Zhao, Xiangqian Guo, Yongping Song
Abstract
Abstract Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20 + NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy. In this study, we summarized several latest reports on CD20 × CD3 bsAbs for the therapy of B-cell NHL from the ASCO 2023 annual meeting (ASCO2023).
Topics & Concepts
CD20MedicineLymphomaHematologyCD3OncologyBispecific antibodyInternal medicineImmunotherapyAntibodyImmunologyCancerMonoclonal antibodyAntigenCD8CAR-T cell therapy researchMonoclonal and Polyclonal Antibodies ResearchLymphoma Diagnosis and Treatment